Syndax Pharmaceuticals, Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Syndax Pharmaceuticals, Inc. (SNDX) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$49.51 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-04
- Syndax Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$49.51M.
- Syndax Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$43.11M.
- Syndax Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was -$60.48M.
- Syndax Pharmaceuticals, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-06-30 was -$72.09M.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month |
|---|---|---|---|
| 2026-06-30 | -$49.51M 10-Q · filed 2026-08-04 | -$92.63M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | -$43.11M 10-Q · filed 2026-04-30 | ||
| 2025-09-30 | -$60.48M 10-Q · filed 2025-11-03 | -$132.56M derived: sum of 2 quarters · filed 2026-08-04 | -$217.05M 10-Q · filed 2025-11-03 |
| 2025-06-30 | -$72.09M 10-Q · filed 2026-08-04 | -$156.57M 10-Q · filed 2026-08-04 | |
| 2025-03-31 | -$84.48M 10-Q · filed 2026-04-30 | ||
| 2024-09-30 | -$82.94M 10-Q · filed 2025-11-03 | -$224.44M 10-Q · filed 2025-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |